Page 3 - Melissab Epperly News Today

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday, Zacks.com reports. According to Zacks, “Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company’s lead programs […]

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) had its target price decreased by SVB Leerink from $78.00 to $67.00 in a research report released on Tuesday, MarketBeat.com reports. SVB Leerink currently has an outperform rating on the stock. A number of other brokerages have also recently weighed in on ZNTL. Wells Fargo & Company initiated coverage […]

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) had its price target reduced by Stifel Nicolaus from $94.00 to $74.00 in a report issued on Monday, The Fly reports. Other analysts have also recently issued research reports about the company. Wells Fargo & Company started coverage on Zentalis Pharmaceuticals in a report on Wednesday, April 6th. They […]

Analysts expect Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) to post ($1.18) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Zentalis Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.30) and the highest estimate coming in at ($1.08). Zentalis Pharmaceuticals reported earnings […]